Helping you make wiser investment decisions

Pharmaceuticals, health and wellness

BioNTech, CureVac part of $3.14B deal to bolster German vaccine capacity through 2029: report

BioNTech, CureVac part of $3.14B deal to bolster German vaccine capacity through 2029: report fkansteiner Wed, 03/16/2022 – 13:19 Source link

AbbVie, Eli Lilly, Novartis and more cut back in Russia amid corporate exodus over Ukraine war

AbbVie, Eli Lilly, Novartis and more cut back in Russia amid corporate exodus over Ukraine war aliu Wed, 03/16/2022 – 11:18 Source link

Lilly and Boehringer's Jardiance, trailing AZ's Farxiga in chronic kidney disease, posts early efficacy win

Lilly and Boehringer’s Jardiance, trailing AZ’s Farxiga in chronic kidney disease, posts early efficacy win fkansteiner Wed, 03/16/2022 – 10:27 Source link

Former J&J CEO Alex Gorsky saw total pay fall last year but remains among pharma's best-paid

Former J&J CEO Alex Gorsky saw total pay fall last year but remains among pharma’s best-paid esagonowsky Wed, 03/16/2022 – 10:27 Source link

Biotech execs who pinched Genentech trade secrets headed to prison

Biotech execs who pinched Genentech trade secrets headed to prison fkansteiner Wed, 03/16/2022 – 09:27 Source link

Viatris' copycat to AstraZeneca blockbuster Symbicort passes FDA muster, but legal battle delays launch

Viatris’ copycat to AstraZeneca blockbuster Symbicort passes FDA muster, but legal battle delays launch esagonowsky Wed, 03/16/2022 – 08:46 Source link

Apellis plots pegcetacoplan FDA filing in blockbuster GA use after revealing 18-month data

Apellis plots pegcetacoplan FDA filing in blockbuster GA use after revealing 18-month data esagonowsky Tue, 03/15/2022 – 13:43 Source link

In rare flop, Merck calls it quits on Keytruda-Lynparza combo in prostate cancer

In rare flop, Merck calls it quits on Keytruda-Lynparza combo in prostate cancer aliu Tue, 03/15/2022 – 11:04 Source link

High-risk lung cancer patients aren’t getting screened, survey shows. What can the industry do?

High-risk lung cancer patients aren’t getting screened, survey shows. What can the industry do? mwen Tue, 03/15/2022 – 10:58 Source link

After trial flop, Exelixis drops plan to pair Cabometyx with Roche's Tecentriq in early-stage liver cancer

After trial flop, Exelixis drops plan to pair Cabometyx with Roche’s Tecentriq in early-stage liver cancer fkansteiner Tue, 03/15/2022 – 10:16 Source link

Progenity starts oral biologic trial in ulcerative colitis after coming through early clinical test

Progenity starts oral biologic trial in ulcerative colitis after coming through early clinical test ntaylor Tue, 03/15/2022 – 09:53 Source link

MHRA request about ultrasound activation system holds up Exact Therapeutics’ solid tumor trial  

MHRA request about ultrasound activation system holds up Exact Therapeutics’ solid tumor trial   ntaylor Tue, 03/15/2022 – 09:42 Source link